Human papillomavirus in cervical cancer and oropharyngeal cancer: One cause, two diseases

Cancer

Volumn 123, Issue 12, 2017, Pages 2219-2229

  Berman, Tara A ^a   Schiller, John T ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

cervical cancer; human papillomavirus (HPV); oropharyngeal cancer; vaccine

Indexed keywords

ADXS 11 001; CANCER VACCINE; CETUXIMAB; NIVOLUMAB; PEMBROLIZUMAB; UNCLASSIFIED DRUG; WART VIRUS VACCINE;

AGE; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER MORTALITY; CANCER PREVENTION; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RISK; CANCER SCREENING; CARCINOGENESIS; CHEMORADIOTHERAPY; DISEASE ASSOCIATION; DRUG EFFICACY; HEAD AND NECK CANCER; HUMAN; IMMUNOMODULATION; IMMUNOTHERAPY; LYMPH NODE DISSECTION; NONHUMAN; OROPHARYNX CANCER; PAPANICOLAOU TEST; PAPILLOMAVIRUS INFECTION; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PREVALENCE; PRIORITY JOURNAL; RADICAL HYSTERECTOMY; REVIEW; RISK FACTOR; SEX DIFFERENCE; SEXUAL BEHAVIOR; UNITED STATES; UTERINE CERVIX CANCER; WART VIRUS; ADENOCARCINOMA; CARCINOMA, SQUAMOUS CELL; EARLY CANCER DIAGNOSIS; FEMALE; HEAD AND NECK NEOPLASMS; INCIDENCE; MALE; OROPHARYNGEAL NEOPLASMS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PROGNOSIS; PROTECTION; UTERINE CERVICAL NEOPLASMS; VIROLOGY;

ADENOCARCINOMA; CARCINOMA, SQUAMOUS CELL; EARLY DETECTION OF CANCER; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; INCIDENCE; MALE; OROPHARYNGEAL NEOPLASMS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PROGNOSIS; PROTECTIVE FACTORS; RISK FACTORS; UTERINE CERVICAL NEOPLASMS;

EID: 85016647166     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.30588     Document Type: Review

References (91)

1. Plummer M, de Martel C, Vignat J, Ferlay J, Bray F, Francheschi S. Global burden of cancers attributable to infections in 2012: a synthetic analysis [serial online]. Lancet Glob Health. 2016;4:e609-e616.
2. Gillison ML, Chaturvedi AK, Anderson WF, Fakhry C. Epidemiology of human papillomavirus-positive head and neck squamous cell carcinoma. J Clin Oncol. 2015;33:3235-3442.
3. Bryan JT, Buckland B, Hammond J, Jansen KU. Prevention of cervical cancer: journey to develop the first human papillomavirus virus-like particle vaccine and the next generation vaccine. Curr Opin Chem Biol. 2016;32:34-47.
4. Cutts FT, Francheschi S, Goldie S, et al. Human papillomavirus and HPV vaccines: a review. Bull World Health Organ. 2007;85:719-726.
5. International Agency for Research on Cancer (IARC)/World Health Organization (WHO). GLOBOCAN 2012: Cervical Cancer Estimated Incidence, Mortality and Prevalence Worldwide in 2012. Lyon, France; IARC; 2012. Available at: http://globocan.iarc.fr/old/FactSheets/cancers/cervix-new.asp.
6. Dayyani F, Etzel CJ, Liu M, Ho CH, Lippman SM, Tsao AS. Meta-analysis of the impact of human papillomavirus (HPV) on cancer risk and overall survival in head and neck squamous cell carcinomas (HNSCC) [serial online]. Head Neck Oncol. 2010;2:15.
7. Maxwell JH, Kumar B, Feng FY, et al. Tobacco use in human papillomavirus-positive advanced oropharynx cancer patients related to increased risk of distant metastases and tumor recurrence. Clin Cancer Res. 2010;16:1226-1235.
8. Vokes EE, Agrawal N, Seiwert TY. HPV-associated head and neck cancer [serial online]. J Natl Cancer Inst. 2015;107:djv344.
9. Elrefaey S, Massaro MA, Chiocca S, Chiesa F, Ansarin M. HPV in oropharyngeal cancer: the basics to know in clinical practice. Acta Otorhinolaryngol Ital. 2014;34:299-309.
10. Evans M, Newcombe R, Fiander A, et al. Human papillomavirus-associated oropharyngeal cancer: an observational study of diagnosis, prevalence and prognosis in a UK population [serial online]. BMC Cancer. 2013;13:220.
11. Ries LAG, Melbert D, Krapcho M, et al. eds. SEER Cancer Statistics Review, 1975–2004 (seer.cancer.gov/csr/1975_2004/, based on November 2006 data submission, posted to the SEER web site, 2007). Bethesda, MD: National Cancer Institute; 2007.
12. Frumovitz M. Small- and large-cell neuroendocrine cervical cancer. Oncology (Williston Park). 2016;30:70, 77–78, 93.
13. Sherman ME, Wang SS, Carreon J, Devesa SS. Mortality trends for cervical squamous and adenocarcinoma in the United States. Relation to incidence and survival. Cancer. 2005;103:1258-1264.
14. Chaturvedi AK. Beyond cervical cancer: burden of other HPV-related cancers among men and women. J Adolesc Health. 2010;46(4 suppl):S20-S26.
15. Roberts JN, Kines RC, Katki HA, Lowy DR, Schiller JT. Effect of Pap smear collection and carrageenan on cervicovaginal human papillomavirus-16 infection in a rhesus macaque model. J Natl Cancer Inst. 2011;103:737-743.
16. Cancer Stat Facts; Surveillance, Epidemiology, and End Results (SEER) Program; National Cancer Institute. Cervix Uteri Cancer. Number of new cases and deaths: percent of new cases by age group, 2009–2013. Bethesda, MD: National Cancer Institute; 2016. Available at: https://seer.cancer.gov/statfacts/html/cervix.html.
17. Franceschi S, Herrero R, Clifford GM, et al. Variations in the age-specific curves of human papillomavirus prevalence in women worldwide. Int J Cancer. 2006;119:2677-2684.
18. Munoz N, Mendez F, Posso H, et al. Incidence, duration, and determinants of cervical human papillomavirus infection in a cohort of Colombian women with normal cytological results. J Infect Dis. 2004;190:2077-2087.
19. Gravitt PE. The known unknowns of HPV natural history. J Clin Invest. 2011;121:4593-4599.
20. Markowitz LE, Dunne EF, Saraiya M, et al. Human papillomavirus vaccination: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2014;63(RR-05):1-30.
21. Moscicki AB, Schiffman M, Kjaer S, Villa LL. Chapter 5: updating the natural history of HPV and anogenital cancer. Vaccine. 2006;24(suppl 3):S3/42-51.
22. Carter JJ, Koutsky LA, Hughes JP, et al. Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection. J Infect Dis. 2000;181:1911-1919.
23. Beachler DC, Jenkens G, Safaeian M, Kreimer AR, Wentzensen N. Natural acquired immunity against subsequent genital human papillomavirus infection: a systematic review and meta-analysis. J Infect Dis. 2016;213:1444-1454.
24. Chaturvedi AK, Engels EA, Pfeiffer RM, et al. Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol. 2011;29:4294-4301.
25. O'Sullivan B, Huang SH, Su J, et al. Development and validation of a staging system for HPV-related oropharyngeal cancer by the International Collaboration on Oropharyngeal Cancer Network for Staging (ICON-S): a multicentre cohort study. Lancet Oncol. 2016;17:440-451.
26. Centers for Disease Control and Prevention (CDC). HPV-Associated Cancer Statistics, 2016. http://www.cdc.gov/cancer/hpv/statistics/index.htm. Accessed March 8, 2017.
27. Nasman A, Attner P, Hammarstedt L, et al. Incidence of human papillomavirus (HPV) positive tonsillar carcinoma in Stockholm, Sweden: an epidemic of viral-induced carcinoma? Int J Cancer. 2009;125:362-366.
28. Sturgis EM, Cinciripini PM. Trends in head and neck cancer incidence in relation to smoking prevalence: an emerging epidemic of human papillomavirus-associated cancers? Cancer. 2007;110:1429-1435.
29. Forman D, de Martel C, Lacey CJ, et al. Global burden of human papillomavirus and related diseases. Vaccine. 2012;30(suppl 5):F12-F23.
30. Polednak AP, Phillips C. Cancers coded as tongue not otherwise specified: relevance to surveillance of human papillomavirus-related cancers. J Registry Manag. 2014;41:190-195.
31. Gillison ML, Broutian T, Pickard RK, et al. Prevalence of oral HPV infection in the United States, 2009-2010. JAMA. 2012;307:693-703.
32. Kjaer SK, Chackerian B, van den Brule AJ, et al. High-risk human papillomavirus is sexually transmitted: evidence from a follow-up study of virgins starting sexual activity (intercourse). Cancer Epidemiol Biomarkers Prev. 2001;10:101-106.
33. Herrero R, Quint W, Hildesheim A, et al. Reduced prevalence of oral human papillomavirus (HPV) 4 years after bivalent HPV vaccination in a randomized clinical trial in Costa Rica [serial online]. PLoS One. 2013;8:e68329.
34. Ho GY, Studentsov Y, Hall CB, et al. Risk factors for subsequent cervicovaginal human papillomavirus (HPV) infection and the protective role of antibodies to HPV-16 virus-like particles. J Infect Dis. 2002;186:737-742.
35. Lu B, Viscidi RP Wu Y, et al. Prevalent serum antibody is not a marker of immune protection against acquisition of oncogenic HPV16 in men. Cancer Res. 2012;72:676-685.
36. D'Souza G, Dempsey A. The role of HPV in head and neck cancer and review of the HPV vaccine. Prev Med. 2011;53(suppl 1):S5-S11.
37. Hitchman SC, Fong GT. Gender empowerment and female-to-male smoking prevalence ratios. Bull World Health Organ. 2011;89:195-202.
38. Slade T, Chapan C, Swift W, Keyes K, Tonks Z, Teesson M. Birth cohort trends in the global epidemiology of alcohol use and alcohol-related harms in men and women: systematic review and metaregression [serial online]. BMJ Open 6:e011827, 2016.
39. van Monsjou HS, Balm AJ, van den Brekel MM, Wreesman VB. Oropharyngeal squamous cell carcinoma: a unique disease on the rise? Oral Oncol. 2010;46:780-785.
40. Heck JE, Berthiller J, Vaccarella S, et al. Sexual behaviours and the risk of head and neck cancers: a pooled analysis in the International Head and Neck Cancer Epidemiology (INHANCE) consortium. Int J Epidemiol. 2010;39:166-181.
41. D'Souza G, Gross ND, Pai SI, et al. Oral human papillomavirus (HPV) infection in HPV-positive patients with oropharyngeal cancer and their partners. J Clin Oncol. 2014;32:2408-2415.
42. Harper DM, Demars LR. Primary strategies for HPV infection and cervical cancer prevention. Clin Obstet Gynecol. 2014;57:256-278.
43. Belz GT, Smith CM, Kleinert L, et al. Distinct migrating and nonmigrating dendritic cell populations are involved in MHC class I-restricted antigen presentation after lung infection with virus. Proc Natl Acad Sci U S A. 2004;101:8670-8675.
44. Partridge JM, Hughes JP, Feng Q, et al. Genital human papillomavirus infection in men: incidence and risk factors in a cohort of university students. J Infect Dis. 2007;196:1128-1136.
45. Kim J, Kim BK, Lee CH, Seo SS, Park SY, Roh JW. Human papillomavirus genotypes and cofactors causing cervical intraepithelial neoplasia and cervical cancer in Korean women. Int J Gynecol Cancer. 2012;22:1570-1576.
46. Hogewoning CJ, Bleeker MC, van den Brule AJ, et al. Condom use promotes regression of cervical intraepithelial neoplasia and clearance of human papillomavirus: a randomized clinical trial. Int J Cancer. 2003;107:811-816.
47. Fakhry C, Andersen KK, Chrlistensen J, Agrawal N, Eisele DW. The impact of tonsillectomy upon the risk of oropharyngeal carcinoma diagnosis and prognosis in the Danish Cancer Registry. Cancer Prev Res (Phila). 2015;8:583-589.
48. Lesseur C, Diegaarde B, Olshan AF, et al. Genome-wide association analyses identify new susceptibility loci for oral cavity and pharyngeal cancer. Nat Genet. 2016;48:1544-1550.
49. Wilke CM, Hall BK, Hoge A, Paradee W, Smith DI, Glover TW. FRA3B extends over a broad region and contains a spontaneous HPV16 integration site: direct evidence for the coincidence of viral integration sites and fragile sites. Hum Mol Genet. 1996;5:187-195.
50. Popescu NC, DiPaolo JA, Amsbaugh SC. Integration sites of human papillomavirus 18 DNA sequences on HeLa cell chromosomes. Cytogenet Cell Genet. 1987;44:58-62.
51. Piyathilake CJ, Henao OL, Macaluso M, et al. Folate is associated with the natural history of high-risk human papillomaviruses. Cancer Res. 2004;64:8788-8793.
52. Piyathilake CJ, Macaluso M, Chambers MM, et al. Folate and vitamin B12 may play a critical role in lowering the HPV 16 methylation-associated risk of developing higher grades of CIN. Cancer Prev Res (Phila). 2014;7:1128-1137.
53. Piyathilake CJ, Ollberding NJ, Kumar R, Macaluso M, Alvarez RD, Morrow CD. Cervical microbiota associated with higher grade cervical intraepithelial neoplasia in women infected with high-risk human papillomaviruses. Cancer Prev Res (Phila). 2016;9:357-366.
54. Doorbar J, Egawa N, Griffin H, Kranjec C, Murkami I. Human papillomavirus molecular biology and disease association. Rev Med Virol. 2015;25(suppl 1):2-23.
55. Kines RC, Cerio RJ, Roberts JN, et al., Human papillomavirus capsids preferentially bind and infect tumor cells. Int J Cancer. 2016; 138:901–911.
56. Roberts JN, Buck CB, Thompson CD, et al. Genital transmission of HPV in a mouse model is potentiated by nonoxynol-9 and inhibited by carrageenan. Nat Med. 2007;13:857-861.
57. Roman A, Munger K. The papillomavirus E7 proteins. Virology. 2013;445:138-168.
58. Vande Pol SB, Klingelhutz AJ. Papillomavirus E6 oncoproteins. Virology. 2013;445:115-137.
59. Chai RC, Lambie D, Verma M, Punyadeera C. Current trends in the etiology and diagnosis of HPV-related head and neck cancers. Cancer Med. 2015;4:596-607.
60. Doorbar J, Quint W, Banks L, et al. The biology and life-cycle of human papillomaviruses. Vaccine. 2012;30(suppl 5):F55-F70.
61. Moscicki AB, Schiffman M, Burchell A, et al. Updating the natural history of human papillomavirus and anogenital cancers. Vaccine. 2012;30(suppl 5):F24-F33.
62. Chi AC, Day TA, Neville BW. Oral cavity and oropharyngeal squamous cell carcinoma–an update. CA Cancer J Clin. 2015. 65:401–421.
63. NCCN Clinical PracticeNational Comprehensive Cancer Network (NCCN). Guidelines in Oncology: Cervical Cancer, Version 1.2017.
64. DeVita Jr. VT, Lawrence TS, Rosenberg SA. DeVita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 2015, Philadelphia: Wolters-Kluwer.
65. Rosenberg SA. DeVita, Hellman, Rosenberg's. Cancer: Principles & Practice of Oncology. 2015, Philadelphia: Wolters-Kluwer.
66. Tewari KS, Sill MW, Long HJ 3rd, et al. Improved survival with bevacizumab in advanced cervical cancer. N Engl J Med. 2014;370:734-743.
67. Tewari KS. Clinical implications for cediranib in advanced cervical cancer. Lancet Oncol. 2015;16:1447–1448.
68. US Food and Drug Administration (FDA). Approved Drugs. Nivolumab for SSCHN. Available at: http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm528920.htm. Accessed December 2, 2016.
69. Frenel JS, Le Tourneau C, O'Neil BH, et al. Pembrolizumab in patients with advanced cervical squamous cell cancer: preliminary results from the phase Ib KEYNOTE-0000 study. Abstract 2016 ASCO.
70. Lheureux S, Butler MO, Fleming GF, et al. A phase 1/2 study of ipilimumab in women with metastatic or recurrent HPV-related cervical carcinoma: A study of the Princess Margaret and Chicago N01 Consortia. Abstract 2014 ASCO.
71. Minion, L.E. and K.S. Tewari, The safety and efficacy of bevacizumab in the treatment of patients with recurrent or metastatic cervical cancer. Expert Rev Anticancer Ther, 2016.
72. Basu P, Mehta AO, Jain MM, et al. ADXS11-001 immunotherapy targeting HPV-E7: final results from a phase 2 study in Indian women with recurrent/refractory cervical cancer. J Iimmunother Cancer. 2013;1:231. 2014;32(15_suppl (May 20 Supplement)):5610.
73. Wirth LJ. Cetuximab in human papillomavirus-positive oropharynx carcinoma. J Clin Oncol. 2016;34:1289-1291.
74. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006;354:567-578.
75. Ferris RL, Blumenschein G Jr, Fayete J, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med. 2016;375:1856-1867.
76. Scudellari M. HPV: sex, cancer and a virus. Nature. 2013;503:330-332.
77. Gillison ML, Koch WM, Capone RB, et al. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst. 2000;92:709–720.
78. Moore KA 2nd, Mehta V. The growing epidemic of HPV-positive oropharyngeal carcinoma: a clinical review for primary care providers. J Am Board Fam Med. 2015;28:498-503.
79. Misiukiewicz K, Camille N, Gupta V, et al. The role of HPV status in recurrent/metastatic squamous cell carcinoma of the head and neck. Clin Adv Hematol Oncol. 2014;12:812-819.
80. Mitra A, MacIntyre DA, Lee YS, et al. Cervical intraepithelial neoplasia disease progression is associated with increased vaginal microbiome diversity. Sci Rep. 2015;5:16865.
81. Lowy DR, Solomon D, Hildesheimn A, Schiller JT, Schiffman M. Human papillomavirus infection and the primary and secondary prevention of cervical cancer. Cancer. 2008;113(7 suppl):1980-1993.
82. Ronco G, Dillner J, Elfstrom KM, et al. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of 4 European randomised controlled trials. Lancet. 2014;383:524-532.
83. Kreimer AR, Chaturvedi AK. HPV-associated oropharyngeal cancers—are they preventable? Cancer Prev Res (Phila). 2011;4:1346-1349.
84. Hensley ML, ed. ASCO-SEP: Medical Oncology Self-Evaluation Program. Alexandria, VA: American Society of Clinical Oncology, Inc; 2016.
85. Joura EA, Giuliano AR, Iversen OE, et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med. 2015;372:711-723.
86. Schiller JT, Castellsague X, Garland SM. A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine. 2012;30(suppl 5):F123-F138.
87. Cuburu N, Schiller JT. Moving forward with human papillomavirus immunotherapies. Hum Vaccin Immunother. 2016;12:2875-2880.
88. The University of Texas Health Science Center. Phase II Evaluation of AHCC for the Eradication of HPV Infections (AHCC4HPV) (clinicaltrials.gov identifier NCT02405533). Available at: https://clinicaltrials.gov/ct2/show/NEC02405533.
89. Mallet JF, Graham E, Ritz BW, Homma K, Matar C. Active hexose correlated compound (AHCC) promotes an intestinal immune response in BALB/c mice and in primary intestinal epithelial cell culture involving toll-like receptors TLR-2 and TLR-4. Eur J Nutr. 2016;55:139-146.
90. Hirose A, Sato E, Fujii H, Sun B, Nishioka H, Aruoma OI. The influence of active hexose correlated compound (AHCC) on cisplatin-evoked chemotherapeutic and side effects in tumor-bearing mice. Toxicol Appl Pharmacol. 2007;222:152-158.
91. Matsui Y, Uhara J, Satoi S, et al. Improved prognosis of postoperative hepatocellular carcinoma patients when treated with functional foods: a prospective cohort study. J Hepatol. 2002;37:78-86.